Skip to content

002880.SZ

Shenzhen Weiguang Biological Products Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 20.50
−2.94%
Ask drillr

Year over year

Reported trailing growth

Revenue
+5.1%
EBITDA
EBIT
-8.3%
EPS
-6.8%
Free cash flow
-39.3%
Operating cash flow
-41.0%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+23.8%
EBITDA
+29.4%
EBIT
+27.1%
Net income
+28.0%
EPS
+28.0%
Free cash flow
+16.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026